中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
(4-甲酰基-2-甲氧基苯氧基)乙酸 | (4-formyl-2-methoxyphenoxy)acetic acid | 1660-19-1 | C10H10O5 | 210.186 |
—— | Ethyl 2-[4-(hydroxyiminomethyl)-2-methoxyphenoxy]acetate | 932796-56-0 | C12H15NO5 | 253.255 |
香草醛 | vanillin | 121-33-5 | C8H8O3 | 152.15 |
香草乙酮 | 1-(3-methoxy-4-hydroxyphenyl)ethanone | 498-02-2 | C9H10O3 | 166.177 |
1-(4-苄氧基-3-甲氧基-苯基)-2-(2-甲氧基-苯氧基)-乙酮 | 1-(4-(benzyloxy)-3-methoxyphenyl)-2-(2-methoxyphenoxy)ethan-1-one | 22317-29-9 | C23H22O5 | 378.425 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
(4-甲酰基-2-甲氧基苯氧基)乙酸 | (4-formyl-2-methoxyphenoxy)acetic acid | 1660-19-1 | C10H10O5 | 210.186 |
4-(2-羟乙氧基)-3-甲氧基苯甲醛 | 4-(2-hydroxyethoxy)-3-methoxybenzaldehyde | 64673-04-7 | C10H12O4 | 196.203 |
4-羧基甲氧基-3-甲氧基-苯甲酸 | (Carboxymethyl)vanillinsaeure | 19345-44-9 | C10H10O6 | 226.186 |
—— | ethyl 2-(2-methoxy-4-(prop-1-enyl)phenoxy)acetate | 632290-89-2 | C14H18O4 | 250.295 |
—— | Ethyl [2-methoxy-4-(1-propen-1-yl)phenoxy]acetate | 1395081-54-5 | C14H18O4 | 250.295 |
—— | 2-(4-formyl-2-methoxyphenoxy)-N,N-dimethylacetamide | 91641-85-9 | C12H15NO4 | 237.255 |
(2-甲氧基-4-丙烯基苯氧基)-乙酸 | (E)-2-(2-methoxy-4-(prop-1-enyl)phenoxy)acetic acid | 7510-46-5 | C12H14O4 | 222.241 |
—— | ethyl [4-(1,3-dioxolan-2-yl)-2-methoxyphenoxy]acetate | 72676-98-3 | C14H18O6 | 282.293 |
—— | 2-(4-(hydroxymethyl)-2-methoxyphenoxy)ethanol | 936478-21-6 | C10H14O4 | 198.219 |
—— | 1-(3-methoxy-4-hydroxyphenyl)-7-(4-oxoacetoxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione | 1347750-39-3 | C23H22O8 | 426.423 |
In this study, a novel series of 1,2-disubstituted benzo[d]imidazoles was rationally designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. Our design strategy is two-fold; it aimed first at studying the effect of replacing the 5-methylfuryl moiety of the well-known antiangiogenic 2-furylbenzimidazoles with an isopropyl moiety on the VEGFR-2 inhibitory activity and the cytotoxic activity. Our second objective was to further optimize the structures of the benzimidazole derivatives through elongation of the side chains at their one-position for the design of more potent type II-like VEGFR-2 inhibitors. The designed 1,2-disubstituted benzimidazoles demonstrated potent cytotoxic activity against the HepG2 cell line, reaching IC50 = 1.98 μM in comparison to sorafenib (IC50 = 10.99 μM). In addition, the synthesized compounds revealed promising VEGFR-2 inhibitory activity in the HepG2 cell line, e.g., compounds 17a and 6 showed 82% and 80% inhibition, respectively, in comparison to sorafenib (% inhibition = 92%). Studying the effect of 17a on the HepG2 cell cycle demonstrated that 17a arrested the cell cycle at the G2/M phase and induced a dose-dependent apoptotic effect. Molecular docking studies of the synthesized 1,2-disubstituted benzimidazoles in the VEGFR-2 active site displayed their ability to accomplish the essential hydrogen bonding and hydrophobic interactions for optimum inhibitory activity.
Advanced lignin model polymers have been synthesised to aid in the development of new methods for lignin valorisation.